Skip to main content
S&P 5007,691.02+1.61%DOW53,363.17+3.04%NASDAQ25,748.76+1.48%BTC$80,053.00+2.92%ETH$2,414.72+5.49%GOLD$4,073.50+3.38%OIL$88.61-7.78%
Smart Investors Daily
SID Premium
KP

NASDAQ · KPRX

Kiora Pharmaceuticals, Inc.

Healthcare · Biotechnology

$1.73

Down-$0.09 (-5.20%)

Updated Nov 4, 2026, 8:52 PM

SID Score

2.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
7.92M
P/E ratio
-0.72
Dividend yield
0.00%
52-week range
$1.55 – $2.91
Volume
40.51K
Avg. volume
47.38K

Price performance · KPRX

KPRX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

KPRX closed at $1.73 after 21 trading sessions, down 30.80% for the selected period.

Last close
$1.73
Period change
-30.80%
Period low
$1.56
Period high
$2.56
Daily close
View OHLC price history
KPRX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$1.72$1.83$1.62$1.7340.51K
Nov 2, 2026$1.65$1.85$1.6101$1.63270.92K
Oct 30, 2026$1.78$1.825$1.55$1.56100.69K
Oct 29, 2026$2.21$2.22$1.73$1.76490.62K
Oct 28, 2026$2.32$2.57$2.32$2.3630.28K
Oct 27, 2026$2.20$2.31$2.20$2.3016.52K
Oct 26, 2026$2.28$2.28$2.21$2.2124.98K
Oct 23, 2026$2.32$2.37$2.24$2.2924.42K
Oct 22, 2026$2.36$2.36$2.32$2.32870
Oct 21, 2026$2.35$2.37$2.32$2.3430.13K
Oct 20, 2026$2.38$2.41$2.32$2.3323.46K
Oct 19, 2026$2.37$2.38$2.36$2.383.37K
Oct 16, 2026$2.42$2.42$2.36$2.4011.89K
Oct 15, 2026$2.46$2.46$2.35$2.4125.39K
Oct 14, 2026$2.47$2.49$2.45$2.4718.33K
Oct 13, 2026$2.55$2.55$2.47$2.472.97K
Oct 12, 2026$2.53$2.56$2.52$2.5612.77K
Oct 9, 2026$2.515$2.57$2.515$2.544.49K
Oct 8, 2026$2.52$2.54$2.48$2.5324.28K
Oct 7, 2026$2.51$2.54$2.49$2.5321.01K
Oct 6, 2026$2.52$2.62$2.50$2.5020.2K

Latest KPRX news

The latest Smart Investors Daily articles mentioning KPRX.

Stock researchCompany · Overview

KPRX research

Overview

Company profile and research snapshot.

Company profile

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
KPRX recent ratings
DateFirmRatingTarget
Sep 2, 2025HC Wainwright & Co.Buy—
Mar 28, 2025HC Wainwright & Co.Buy—
Nov 12, 2024HC Wainwright & Co.Buy—
Aug 22, 2024HC Wainwright & Co.Buy—
Jul 23, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 29, 2026

Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Trial in CRAO in Japan

The oral small-molecule calpain inhibitor demonstrated meaningful visual acuity improvement in Phase 2 and Phase 3 CRAO studies conducted in Japan compared to controls.No therapeutics exist today to treat patients that experience CRAO vision loss.Kiora plans to advance KIO-401 (mitucapistat) into a multinational Phase 3 registration trial in CRAO, with initiation targeted for 2027.Company also plans to evaluate KIO-401 in a Phase 2b clinical trial in non-arteritic anterior ischemic optic...

Yahoo · Sep 8, 2026

Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs

Clinical development executive brings over 20 years of ophthalmology experience supporting U.S. and global clinical trials to support the advancement of Kiora's pipeline and new asset opportunitiesEncinitas, California--(Newsfile Corp. - September 8, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced the appointment of Keith J. Lane, MBA, as Executive Vice President of Clinical Development and Regulatory Affairs. Mr. Lane has over 20 years of experience

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By